Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study
Summary Background Therapeutic management of inflammatory bowel diseases (IBD) is rapidly evolving, with an expanding armoury of biological drugs at our disposal. However, real‐world findings about treatment persistence and the impact of biologicals on surgery remain inconsistent. Aims This study aimed to investigate trends in biological use and surgery rates in a nationwide cohort of biological‐naïve IBD patients. Methods Patients with IBD who initiated biological treatment between 2011 and 2018 were identified in the Danish National Patient Registry. Data on use of biologicals, surgeries and healthcare costs were retrieved and analysed for time trends. Results Between 2011 and 2018, a total of 6,036 IBD (51% ulcerative colitis (UC), 49% Crohn's disease (CD)) patients received biological treatment for the first time. Cumulative use of biologicals increased from 5.0% to 10.8% among UC and 8.9%‐14.5% among CD patients. Infliximab remained the most‐prescribed first‐line biological for UC and CD. Treatment persistence was 44.3% and 16.9% after 1 and 3 years in UC, compared to 59.9% and 33.6% in CD patients. Overall, 32.8% of patients switched to a second biological. Surgery rates decreased in both UC ( P = 0.015) and CD ( P = 0.008) patients and remained significant for UC in the Cox regression model ( P = 0.002). Outpatient and surgical costs also fell among both UC and CD patients. Conclusions Persistence rates for first‐line biologicals among IBD patients were low and one‐third switched treatment. Surgery rates and direct costs decreased over time, but whether this is related to the use of biologicals has yet to be determined..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Alimentary Pharmacology & Therapeutics - 55(2022), 5, Seite 541-557 |
| Beteiligte Personen: |
Zhao, Mirabella [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2022 John Wiley & Sons Ltd |
|---|
| Umfang: |
17 |
|---|
| doi: |
10.1111/apt.16723 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002342944 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002342944 | ||
| 003 | DE-627 | ||
| 005 | 20230307114653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/apt.16723 |2 doi | |
| 028 | 5 | 2 | |a APT_APT16723.xml |
| 035 | |a (DE-627)WLY002342944 | ||
| 035 | |a (WILEY)APT16723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Zhao, Mirabella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study |
| 264 | 1 | |c 2022 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 John Wiley & Sons Ltd | ||
| 520 | |a Summary Background Therapeutic management of inflammatory bowel diseases (IBD) is rapidly evolving, with an expanding armoury of biological drugs at our disposal. However, real‐world findings about treatment persistence and the impact of biologicals on surgery remain inconsistent. Aims This study aimed to investigate trends in biological use and surgery rates in a nationwide cohort of biological‐naïve IBD patients. Methods Patients with IBD who initiated biological treatment between 2011 and 2018 were identified in the Danish National Patient Registry. Data on use of biologicals, surgeries and healthcare costs were retrieved and analysed for time trends. Results Between 2011 and 2018, a total of 6,036 IBD (51% ulcerative colitis (UC), 49% Crohn's disease (CD)) patients received biological treatment for the first time. Cumulative use of biologicals increased from 5.0% to 10.8% among UC and 8.9%‐14.5% among CD patients. Infliximab remained the most‐prescribed first‐line biological for UC and CD. Treatment persistence was 44.3% and 16.9% after 1 and 3 years in UC, compared to 59.9% and 33.6% in CD patients. Overall, 32.8% of patients switched to a second biological. Surgery rates decreased in both UC ( P = 0.015) and CD ( P = 0.008) patients and remained significant for UC in the Cox regression model ( P = 0.002). Outpatient and surgical costs also fell among both UC and CD patients. Conclusions Persistence rates for first‐line biologicals among IBD patients were low and one‐third switched treatment. Surgery rates and direct costs decreased over time, but whether this is related to the use of biologicals has yet to be determined. | ||
| 700 | 1 | |a Sall Jensen, Morten |4 aut | |
| 700 | 1 | |a Knudsen, Torben |4 aut | |
| 700 | 1 | |a Kelsen, Jens |4 aut | |
| 700 | 1 | |a Coskun, Mehmet |4 aut | |
| 700 | 1 | |a Kjellberg, Jakob |4 aut | |
| 700 | 1 | |a Burisch, Johan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary Pharmacology & Therapeutics |g 55(2022), 5, Seite 541-557 |w (DE-627)WLY002324040 |x 13652036 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g number:5 |g pages:541-557 |g extent:17 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |e 5 |h 541-557 |g 17 | ||